Welcome to our dedicated page for Cartesian Therapeutics SEC filings (Ticker: RNAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cartesian Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cartesian Therapeutics's regulatory disclosures and financial reporting.
JPMorgan Chase & Co. filed an amended Schedule 13G reporting its beneficial ownership in Cartesian Therapeutics, Inc. (common stock). The firm reports beneficial ownership of 1,486,252 shares of common stock, representing 4.8% of the class as of June 30, 2026. JPMorgan Chase & Co. has sole voting power over 1,397,213 shares and sole dispositive power over 1,486,252 shares, with no shared voting or dispositive power. The filing notes that this represents ownership of 5 percent or less of the class, and identifies JPMorgan Chase Bank, National Association, and J.P. Morgan Investment Management Inc. as relevant subsidiaries.
Cartesian Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. A total of 24,151,536 common shares were represented, equal to approximately 82.42% of shares outstanding as of the April 14, 2026 record date, indicating strong turnout.
Stockholders elected three Class I directors to serve until the 2029 Annual Meeting. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting proposed and recent transactions in Common stock of RNAC. The filing lists planned exercises and restricted-stock vesting dated 06/09/2026 and 01/02/2026
The filing also reports a disposition by Milos Miljkovic of 3,924 shares on 06/02/2026 for $25,152.84. The itemized entries show multiple issuances/exercises under registered plans with share counts explicitly listed.
Cartesian Therapeutics entered a strategic licensing agreement with WestGene Biopharma to develop novel in vivo CAR-T therapies for autoimmune diseases. The collaboration combines Cartesian’s mRNA payload from Descartes-08 with WestGene’s targeted lipid nanoparticle platform.
WestGene’s in vivo mRNA CAR-T platform has early clinical data showing favorable safety, including repeated dosing of up to 14 infusions in a single patient with only one Grade 1 cytokine release syndrome event reported. The partners plan a Phase 1 dose-escalation study in generalized myasthenia gravis using mRNA from Descartes-08 delivered via WestGene’s nanoparticles, with trial initiation expected in the second half of 2026 and first clinical data expected in the first half of 2027.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice concerning proposed sales of Common stock tied to restricted stock vesting under a registered plan. The excerpt lists proposed sale entries with dates 01/02/2025 and 01/02/2026, and a filing-related date of 06/02/2026.
The notice identifies amounts and line items such as 3924, 1,235, and 2,689 associated with the vesting entries; the filing shows the broker name and NASDAQ as the market. Timing and cash‑flow treatment for any transactions are not specified in the provided excerpt.
Cartesian Therapeutics entered a senior secured Loan and Security Agreement providing up to $150.0 million in term loans from K2 HealthVentures, with an initial $50.0 million tranche funded and additional tranches tied to clinical, approval and sales milestones or lender discretion.
The debt matures on June 1, 2030, bears interest at the greater of 8.95% or the prime rate plus 2.20%, and includes minimum cash and future revenue covenants as the company advances Descartes-08 through late-stage trials.
Lenders may convert up to $15.0 million of principal into common stock at $8.2526 per share or qualifying financing prices, subject to ownership caps. The company expects the initial funding to extend its cash runway into 2028 while it targets key data readouts and a planned BLA filing in 2027. Chief Medical Officer Milos Miljkovic, M.D., is resigning effective May 31, 2026, with severance consistent with his employment agreement.
CARTESIAN THERAPEUTICS INC ownership update: institutional investor FMR LLC reports beneficial ownership of 799,743 shares of Common Stock, representing 3.0% of the class as of 03/31/2026. The filing also lists Abigail P. Johnson with dispositive power over the same 799,743 shares.
The filing is an Amendment No. 4 to a Schedule 13G/A and includes a reference to a 13d-1(k) agreement in Exhibit 99 and a power of attorney incorporated by reference.
Cartesian Therapeutics, Inc. reported a first-quarter 2026 net loss of $39.2 million, wider than the prior year, as it increased investment in its lead cell therapy programs and recorded a higher fair value for contingent value rights.
Revenue was minimal at $0.1 million, all from a government grant, with no collaboration revenue recognized. Research and development expenses rose to $19.5 million, driven mainly by Phase 3 work on Descartes-08 for myasthenia gravis, while general and administrative costs declined to $7.1 million.
The company ended the quarter with $120.4 million in cash, cash equivalents and restricted cash and raised about $14.6 million through an at-the-market stock offering, and believes this liquidity will fund planned operations for at least the next 12 months.
Cartesian Therapeutics reported first quarter 2026 results and updated progress on its Descartes-08 cell therapy pipeline. Cash, cash equivalents and restricted cash were $120.4 million as of March 31, 2026, which the company expects will fund planned operations into mid-2027, including completion of the ongoing Phase 3 AURORA trial in myasthenia gravis.
For the quarter, total revenues were $78 thousand versus $1.1 million a year earlier, while research and development expenses rose to $19.5 million from $14.7 million, and general and administrative expenses declined to $7.1 million from $8.3 million. Net loss widened to $39.2 million, or $1.46 per basic share, compared with $17.7 million, or $0.68 per basic share, in the prior-year period.
The company highlighted ongoing enrollment in the randomized, placebo-controlled Phase 3 AURORA trial of Descartes-08 in acetylcholine receptor antibody–positive myasthenia gravis, initiation of the Phase 2 TRITON trial in multi-refractory myositis, and enrollment of multiple patients in the pediatric Phase 1/2 HELIOS trial in juvenile dermatomyositis. Descartes-08 is an autologous BCMA-targeting CAR-T designed for outpatient administration without preconditioning chemotherapy and has received multiple U.S. FDA designations, including Orphan Drug and Regenerative Medicine Advanced Therapy designations in myasthenia gravis and Rare Pediatric Disease designation in juvenile dermatomyositis.
Cartesian Therapeutics, Inc. will hold its 2026 Annual Meeting virtually on June 12, 2026 at 10:00 a.m. Eastern Time. Stockholders will vote to elect three Class I directors to terms ending in 2029, approve on a non-binding basis executive compensation, and ratify Ernst & Young LLP as auditor for 2026.
Holders of 29,302,729 shares of common stock outstanding as of April 14, 2026 are entitled to one vote per share and may vote by internet, telephone, mail, or during the virtual meeting. The proxy also outlines board structure, committee responsibilities, and a pay program emphasizing variable, equity-based compensation tied to company performance.